High Incidence of Non-Alcoholic Fatty Liver Disease Among Statin-Naïve Patients With Newly Diagnosed Coronary Artery Disease.

Abstract Background: Non-Alcoholic Fatty Liver Disease (NAFLD) refers to a spectrum of disorders occurring in the liver, which share a common pathophysiological pathway with coronary atherosclerosis . Aim: The study aimed to evaluate the prevalence of NAFLD among patients with evidence of detectable coronary atherosclerotic burden through a CT coronary angiography Methods: Our cross-sectional study enrolled 150 patients with intermediate pretest probability for coronary artery disease who were scheduled for a cardiac CT scan at the Armed Forces College of Medicine, Cairo, Egypt, between December 2023 and September 2024. Patients who had any measurable coronary plaque burden were enrolled in the study, and the volume of which was calculated; then their liver status was assessed by FibroScan for the assessment of hepatic steatosis and liver fibrosis. Other parameters, including weight, height, body mass index (BMI), waist circumference, and several laboratory findings, were correlated with the main findings. Coronary artery calcium scoring was also calculated and correlated with the main findings Results: NAFLD was evident in 65.3% of the study group. Liver fibrosis was significantly correlated with body weight, BMI, waist circumference, and serum triglyceride level. In the NAFLD group, liver steatosis was significantly related to coronary plaque volume and coronary calcium score. Conclusion: There were also strong associations between metabolic risk factors, coronary plaque burden, and liver fibrosis. Routine screening for NAFLD in such patients could help improve risk stratification.